CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6,617 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01078233
NCT01078233N/ACompleted
CompareCT.gov

Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period

Merck Sharp & Dohme LLC·observational·Posted Mar 2, 2010·Updated Nov 25, 2019

In Brief

An observational study for HIV-1 Infections. Completed, enrolled 6,617 participants.

Detailed Summary

The main objective of the study is to monitor health outcomes associated with antiretroviral drugs in a population of HIV-infected patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infections
Countries--
CollaboratorsEuroSIDA Coordinating Centre, Copenhagen HIV Programme (CHIP)

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2, 2010
Enrollment StartMay 5, 2008
Primary CompletionMar 6, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 16.3 years ago